QUANTRO Therapeutics Reaches Milestone in Collaboration with Boehringer Ingelheim

Vienna, Austria, 04 June 2024: QUANTRO Therapeutics has achieved a significant milestone in its collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments. By successfully applying its proprietary QUANTROseq® Transcriptional Fingerprint technology, QUANTRO met all pre-set goals for technical proof-of-concept, cross-validation, and identification of high-quality hits for a previously undruggable transcription factor.

Cancer remains a leading cause of death worldwide with limited treatment options. Transcription factors, central regulators of gene expression often dysregulated in cancer, have emerged as promising therapeutic targets. The joint R&D program, initiated in 2022, aims to develop transformational cancer treatments.

Michael Bauer, CEO of QUANTRO, expressed commitment to advancing innovative cancer treatments in partnership with Boehringer Ingelheim. Norbert Kraut, Global Head of Cancer Research at Boehringer Ingelheim, praised the robust technology proof-of-concept and attractive hits from initial screenings.

QUANTRO will receive an undisclosed milestone payment, adding to previous upfront payments and R&D funding. The total potential transaction value could exceed EUR 500 million.